Get started

Pdufa

$SAGE: strong base, upcoming catalysts$SAGE is an interesting stock here, has pending catalysts for mid 2023, which fit the expectations from the Time@Mode technical pattern at hand here. Consider the volatility of these biotech names when entering, stock could move huge after data comes out (up or down) but odds are good that it breaks to the upside given the technical pattern suggesting the smart money has been accumulating stock. Upcoming catalysts: SAGE-217 - (SHORELINE) Major Depressive Disorder (MDD) Phase 3 additional data due in mid-2023. Zuranolone (SAGE-217) Major depressive disorder (MDD) and Postpartum Depression PDUFA priority review date of August 5, 2023. Best of luck! Cheers, Ivan Labrie.
NASDAQ:SAGELong
by IvanLabrie
1
AGEN digging through the CratesAGEN hasn't done this in years...what? It hasn't sustained these levels for any meaningful amount of time. I did a quick fib retracement using those 2017 highs as the upper anchor and you can see what has revealed itself. The 236 area is a key pivot. Most of the time it has acted as a resistance pivot. But, so far AGEN has held these levels. Where does it go from here? A lot of that might have to do with what's coming. " pipeline treatments like AGEN1777 have gained interest from some of the industry’s leading names. Bristol Myers Squibb ( BMY ) has a global exclusive license with Agenus providing up to $200 million in cash upfront. The company can also receive up to $1.36 billion if it reaches specific milestones and includes royalties upon any sales. The FDA already cleared an Investigational New Drug Application for a Phase 1 dosing with AGEN1777 alone and combined with an anti-PD-1 in solid tumors. That’s expected to begin this quarter...Balstilimab...is something that could be in focus as well. The FDA accepted a Biologics License Application for priority review. A Prescription Drug User Fee Act (PDUFA) target date was also given. December 16th will be the PDUFA date and could present an important one for the company and Balstilimab. Phase 2 data showed a response rate of 20% in PD-L1 positive tumors, an overall response rate of 15%, and a median duration of response of 15.4 months. Furthermore, Phase 2 trial results of balstilimab combined with zalifrelimab (AGEN1884) will be presented at a Mini Oral Session at the European Society for Medical Oncology Congress next month. So plenty to watch if AGEN stock is on your watch list right now. " Quote Source & Read more On AGEN: Hot Biotech Stocks That Deserve Your Attention In August 2021
NASDAQ:AGEN
by PennyStocks101